
Adagene Raises Up to $25M from Sanofi to Advance Muzastotug and SAFEbody Platform
Adagene Inc. (Nasdaq: ADAG), a clinical-stage biotechnology company pioneering novel antibody-based cancer immunotherapies, has secured a strategic investment of up to $25 million from Sanofi (Euronext: SAN FP). The funding, announced today, will drive Adagene’s research and development, particularly the…